Abstract:To improve our understanding of drug-target interactions, we explored the effect of introducing substituted amine residues with increased chain length in the P3 residue of the thrombin inhibitor melagatran. Inhibition, kinetic, and thermodynamic data obtained via stopped-flow spectroscopy (SF), isothermal microcalorimetry (ITC), and surface plasmon resonance (SPR) biosensor analysis were interpreted with the help of X-ray crystal structures of the enzyme-inhibitor complexes. The association rate became faster when the lipophilicity of the inhibitors was increased. This was coupled to an increased enthalpic component and a corresponding decreased entropic component. The dissociation rates were reduced with an increase in chain length, with only a smaller increase and a decrease in the enthalpic and entropic components, respectively. Overall, the affinity increased with an increase in chain length, with similar changes in the enthalpic and entropic components. ITC analysis confirmed the equilibrium data from SPR analysis, showing that the interaction of melagatran was the most enthalpy-driven interaction. Structural analysis of the thrombin-inhibitor complex showed that the orientation of the P1 and P2 parts of the molecules was very similar, but that there were significant differences in the interaction between the terminal part of the P3 side chain and the binding pocket. A combination of charge repulsion, H-bonds, and hydrophobic interactions could be used to explain the observed kinetic and thermodynamic profiles for the ligands. In conclusion, changes in the structure of a lead compound can have significant effects on its interaction with the target that translate directly into kinetic and thermodynamic effects. In contrast to what may be intuitively expected, hydrogen bond formation and breakage are not necessarily reflected in enthalpy gains and losses, respectively.

Comparative Molecular Field Analysis Of Non-Peptidic Inhibitors Of Thrombin

Molecular docking and topomer CoMFA research of phenyl acetamides derivatives as direct thrombin inhibitors

Investigation on the Binding Mode of Benzothiophene Analogues As Potent Factor Ixa (fixa) Inhibitors in Thrombosis by Comfa, Docking and Molecular Dynamic Studies

Structure-Affinity Relationship of Thrombin Inhibitors

Investigation of Interactions Between Thrombin and Ten Phenolic Compounds by Affinity Capillary Electrophoresis and Molecular Docking

Design, Synthesis, Biological Evaluation and Molecular Docking Studies of Dabigatran Analogs As Potential Thrombin Inhibitors

Identification of structural-kinetic and structural-thermodynamic relationships for thrombin inhibitors

Identification of the Functional Food Ingredients with Antithrombotic Properties Via Virtual Screen and Experimental Studies.

Directly Investigating the Interaction Between Aptamers and Thrombin by Atomic Force Microscopy

Comparative Analysis of Pharmacophore Features and Quantitative Structure-Activity Relationships for Cd38 Covalent and Non-Covalent Inhibitors

Comparative Molecular Field Analysis of Tyrosine Kinase Inhibitors

Functional expression of a thrombin exosite I inhibitor triabin in Escherichia coli and elucidation of the role of key residues in its inhibitory activity

Rational Design of Potent, Small, Synthetic Allosteric Inhibitors of Thrombin.

Exosite Binding in Thrombin: A Global Structural/Dynamic Overview of Complexes with Aptamers and Other Ligands

Quantum and Molecular Dynamics Study for Binding of Macrocyclic Inhibitors to Human Α-Thrombin

Structural Determination of Three Different Series of Compounds as Hsp90 Inhibitors Using 3D-QSAR Modeling, Molecular Docking and Molecular Dynamics Methods

COMPUTATIONAL STUDY FOR BINDING OF OSCILLARIN TO HUMAN Α-Thrombin

Selectivity of Neutral/weakly Basic P1 Group Inhibitors of Thrombin and Trypsin by a Molecular Dynamics Study.

Molecular Simulations of the Inhibition of Active Components in Traditional ChineseMedicine on the Thromboxane A2 Receptor

Design, Synthesis, and Thrombin Inhibitory Activity Evaluation of Some Novel Benzimidazole Derivatives

Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition